Hand, Foot, and Mouth Disease: Could EPs® 7630 Be a Treatment Option? A Prospective Randomized Open-label Multicenter Clinical Study

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Jun 4

PMID 38832001

Authors

Murat Sutcu

Manolya Kara

Funda Yildiz

Omer Kilic

Tugce Tural Kara

Gulsen Akkoc

Ayse Buyukcam

Sefika Elmas Bozdemir

Ozlem Ozgur Gundeslioglu

Doruk Gul

Merve Iseri Nepesov

Ates Kara

Affiliations

Soon will be listed here.

Abstract

Purpose: Hand, foot and mouth disease (HFMD) is a viral contagious disease of children caused by human enteroviruses (EVs) and coxsackieviruses (CVs). There is no specific treatment option for HFMD. EPs® 7630's anti-infective and immunomodulatory properties have previously been demonstrated in several and studies; however, the use of this herbal medicine in children with HFMD has not previously been investigated.

Methods: This prospective randomized multicenter clinical study included 208 children with HFMD. The diagnosis was made by pediatricians. The patients who were within the first 48 h of symptom onset (according to the first onset of fever and skin findings) were enrolled. The study participants were assigned into 2 groups as EPs® 7630 and control groups. All patients were followed up twice more, 48 h after the first admission and on the 5th-7th day. Another phone evaluation was conducted for those with continued complaints from the previous visit.

Results: The median age was 27 (12-112) months. The male-female ratio was 0.98. One hundred thirty one (63%) of 190 patients had no history of household contact. EPs® 7630 group included 94 and control group included 96 patients. A significant difference was found between the groups in terms of complaint scores at the visits made at the 48th h of the treatment and on days 5-7 ( < 0.001). The mean ± SD disease duration of EPs® 7630 users was significantly shorter 6.07 ± 0.70 days (95% CI: 5.92-6.21)] than the control group [8.58 ± 0.94 days (95% CI: 8.39-8.77)] ( < 0.001). Besides, the hospitalization rate among the EPs® 7630 users were significantly lower ( = 0.019). No side effects were observed, except for unpleasant taste, which was reported in 5 patients (EPs® 7630 group).

Conclusion: Considering its efficacy and safety profile EPs® 7630 may represent a feasible herbal-based treatment option for children with HFMD.

Clinical Trial Registration: ClinicalTrials.gov, identifier (NCT06353477).

Citing Articles

Unlocking the therapeutic potential of natural extract: A scoping review.

Reina B, Malheiros S, Vieira S, Ferreira de Andrade P, Dovigo L Heliyon. 2024; 10(23):e40554.

PMID: 39654721 PMC: 11625261. DOI: 10.1016/j.heliyon.2024.e40554.

References

Fang Y, Wang S, Zhang L, Guo Z, Huang Z, Tu C . Risk factors of severe hand, foot and mouth disease: a meta-analysis. Scand J Infect Dis. 2014; 46(7):515-22. DOI: 10.3109/00365548.2014.907929. View

Witte K, Koch E, Volk H, Wolk K, Sabat R . The herbal extract EPs® 7630 increases the antimicrobial airway defense through monocyte-dependent induction of IL-22 in T cells. J Mol Med (Berl). 2020; 98(10):1493-1503. PMC: 7524690. DOI: 10.1007/s00109-020-01970-3. View

Ventarola D, Bordone L, Silverberg N . Update on hand-foot-and-mouth disease. Clin Dermatol. 2015; 33(3):340-6. DOI: 10.1016/j.clindermatol.2014.12.011. View

Lizogub V, Riley D, Heger M . Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY). 2007; 3(6):573-84. DOI: 10.1016/j.explore.2007.09.004. View

Miller G, TINDALL J . Hand-foot-and-mouth disease. JAMA. 1968; 203(10):827-30. View

Esposito S, Principi N . Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018; 37(3):391-398. DOI: 10.1007/s10096-018-3206-x. View

Riley D, Lizogub V, Heger M, Funk P, Mueller H, Lehmacher W . Treatment with EPs 7630, a Root Extract, Is Effective and Safe in Patients with the Common Cold: Results From a Randomized, Double Blind, Placebo-Controlled Clinical Trial. Integr Med (Encinitas). 2019; 18(1):42-51. PMC: 6601435. View

Saguil A, Kane S, Lauters R, Mercado M . Hand-Foot-and-Mouth Disease: Rapid Evidence Review. Am Fam Physician. 2019; 100(7):408-414. View

MAGOFFIN R, Jackson E, LENNETTE E . Vesicular stomatitis and exanthem. A syndrome associated with Coxsackie virus, type A16. JAMA. 1961; 175:441-5. DOI: 10.1001/jama.1961.03040060015004. View

10.

Thale C, Kiderlen A, Kolodziej H . Anti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assay. Planta Med. 2010; 77(7):718-25. DOI: 10.1055/s-0030-1250567. View

11.

Repass G, Palmer W, Stancampiano F . Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Cleve Clin J Med. 2014; 81(9):537-43. DOI: 10.3949/ccjm.81a.13132. View

12.

Roth M, Sun Q, Tamm M . Up-Regulated Vitamin D Receptor by Extract EPs 7630 Contributes to Rhinovirus Defense in Bronchial Epithelial Cells. Pharmaceuticals (Basel). 2021; 14(2). PMC: 7926416. DOI: 10.3390/ph14020172. View

13.

Careddu D, Pettenazzo A . extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 2018; 11:91-98. PMC: 5849386. DOI: 10.2147/IJGM.S154198. View

14.

Matthys H, Kamin W, Funk P, Heger M . Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine. 2006; 14 Suppl 6:69-73. DOI: 10.1016/j.phymed.2006.11.015. View

15.

Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C . Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol. 2013; 25(9):1093-8. DOI: 10.1097/MEG.0b013e3283603e89. View

16.

Wang J, Zhou J, Xie G, Zheng S, Lou B, Chen Y . The Epidemiological and Clinical Characteristics of Hand, Foot, and Mouth Disease in Hangzhou, China, 2016 to 2018. Clin Pediatr (Phila). 2020; 59(7):656-662. DOI: 10.1177/0009922820910822. View

17.

Timmer A, Gunther J, Motschall E, Rucker G, Antes G, Kern W . Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev. 2013; (10):CD006323. PMC: 11835051. DOI: 10.1002/14651858.CD006323.pub3. View

18.

Papies J, Emanuel J, Heinemann N, Kulic Z, Schroeder S, Tenner B . Antiviral and Immunomodulatory Effects of Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells. Front Pharmacol. 2021; 12:757666. PMC: 8573200. DOI: 10.3389/fphar.2021.757666. View

19.

Mirand A, Cohen R, Bisseux M, Tomba S, Sellem F, Gelbert N . A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 2021; 26(43). PMC: 8555367. DOI: 10.2807/1560-7917.ES.2021.26.43.2100978. View

20.

Michaelis M, Doerr H, Cinatl Jr J . Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine. 2010; 18(5):384-6. PMC: 7127141. DOI: 10.1016/j.phymed.2010.09.008. View